title: Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.
abstract: The aim of this study was to develop a flow cytometric test to quantitate low levels of circulating myeloma plasma cells, and to determine the relationship of these cells with disease stage. Cells were characterized using five-parameter flow cytometric analysis with a panel of antibodies, and results were evaluated by comparison with fluorescent consensus-primer IgH-PCR. Bone marrow myeloma plasma cells, defined by high CD38 and Syndecan-1 expression, did not express CD10, 23, 30, 34 or 45RO, and demonstrated weak expression of CD37 and CD45. 65% of patients had CD19- 56+ plasma cells, 30% CD19- 56(low), and 5% CD19+ 56+, and these two antigens discriminated myeloma from normal plasma cells, which were all CD19+ 56(low). Peripheral blood myeloma plasma cells had the same composite phenotype, but expressed significantly lower levels of CD56 and Syndecan-1, and were detected in 75% (38/51) of patients at presentation, 92% (11/12) of patients in relapse, and 40% (4/10) of stem cell harvests. Circulating plasma cells were not detectable in patients in CR (n = 9) or normals (n = 10), at a sensitivity of up to 1 in 10,000 cells. There was good correlation between the flow cytometric test and IgH-PCR results: myeloma plasma cells were detectable by flow cytometry in all PCR positive samples, and samples with no detectable myeloma plasma cells were PCR negative. Absolute numbers decreased in patients responding to treatment, remained elevated in patients with refractory disease, and increased in patients undergoing relapse. We conclude that flow cytometry can provide an effective aternative to IgH-PCR that will allow quantitative assessment of low levels of residual disease.
authors.affiliation: Department of Haematology, The General Infirmary at Leeds.
authors.forename: A C
authors.initials: AC
authors.lastname: Rawstron
authors.forename: R G
authors.initials: RG
authors.lastname: Owen
authors.forename: F E
authors.initials: FE
authors.lastname: Davies
authors.forename: R J
authors.initials: RJ
authors.lastname: Johnson
authors.forename: R A
authors.initials: RA
authors.lastname: Jones
authors.forename: S J
authors.initials: SJ
authors.lastname: Richards
authors.forename: P A
authors.initials: PA
authors.lastname: Evans
authors.forename: J A
authors.initials: JA
authors.lastname: Child
authors.forename: G M
authors.initials: GM
authors.lastname: Smith
authors.forename: A S
authors.initials: AS
authors.lastname: Jack
authors.forename: G J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015322:Gene Rearrangement, B-Lymphocyte; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D009367:Neoplasm Staging; D010950:Plasma Cells / Q000473:pathology*; D016133:Polymerase Chain Reaction; D013234:Stem Cells